New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 12, 2024, Sandoz announced the FDA approval of Enzeevu (aflibercept-abzv), biosimilar to Regeneron’s Eylea® (aflibercept).
Download PDF
Return to publications
